Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STM-416p in Prostate Cancer Undergoing Radical Prostatectomy
NCT06450106Phase 1Recruiting
- Sponsor
- SURGE Therapeutics
- Start
- May 2025
- Primary completion
- Sep 2026
- Modality
- Hydrogel Systems, Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of STM-416p in prostate cancer (PCa), sponsored by SURGE Therapeutics. Primary endpoints: Dose-Limiting Toxicities at 21 days and Treatment-Emergent Adverse Events at 90 days. Started May 2025; status: recruiting.
02
Drugs
STM-416p
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT06450106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06450106.